ADA Scientific Sessions 2026 Abstract

Screening Rates and Guideline-Directed Medical Therapy Use for Chronic Kidney Disease in People with Type 2 Diabetes

By Skylar Harrigfeld, Lauren Cunningham, Brian Layden, Anand Srivastava

Study in peoplePopulations

The paper

Skylar Harrigfeld, Lauren Cunningham, Brian Layden, Anand Srivastava

Chicago

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, late-breaking 2704-LB

doi.org/10.2337/db26-2704-lb

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk